{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"37.6","upperLimit":"62.4","value":"50.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"}],"units":"Participants"}],"description":"Participants who attained mUFC ≤ 1.0 x ULN (upper limit of normal) with pasireotide alone or in combination with cabergoline. The 24h-UFC concentration results from three samples, collected during the screening period, were averaged to obtain the Baseline urinary free cortisol level. mean 24h-UFC was determined from two 24-hour urine collections collected on two consecutive days that occurred before the visit. Imputation: subjects who completed the end of treatment visit at Week 35, but had missing evaluation of mean urinary free cortisol (mUFC). The last available mUFC assessment at or after previous visit (week) before last week was carried forward as the last week mUFC assessment.","dispersionType":"95% Confidence Interval","groups":[{"description":"Pasireotide montherapy (0.6 mg bid to 0.9 mg bid) was administered until the biochemical control was achieved and if not achieved, a combination was administered: pasireotide (0.9 mg bid) + cabergoline (0.5 QD to 1 mg QD). Patients were able to add cabergoline at anytime during core and extension","id":"OG000","title":"All Patients"}],"paramType":"NUMBER","populationDescription":"Full analysis set","reportingStatus":"POSTED","timeFrame":"Baseline up to week 35","title":"Percentage of Responders With Mean Urinary Free Cortisol (mUFC) ≤ 1.0xULN Collected or Imputed at Week 35","type":"PRIMARY","unitOfMeasure":"percentage of responders"}